New potential adjuncts to treatment of children with type 1 diabetes mellitus

Vandana S. Raman, Rubina A. Heptulla

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Insulin administration is the primary therapy for type 1 diabetes mellitus (T1DM). Current available insulin therapies do not successfully enable children with T1DM to reach glycemic goals without side effects such as hypoglycemia and weight gain. Pramlintide is a synthetic analog of human amylin that acts in conjunction with insulin to delay gastric emptying and inhibit the release of glucagon and is indicated for use in patients with type 1 and type 2 diabetes. Recent studies in adult patients have examined the role of glucagon-like peptide 1 (GLP-1) and agents that bind to its receptor in type 1 diabetes. It is hypothesized that a major component of the glycemic effect is attributable to the known action of GLP-1 to delay gastric emptying and to inhibit glucagon secretion. Further studies with the use of amylin analogs and long-acting GLP-1 agonists as congeners with insulin in T1DM are indicated in children. In recent years, our better understanding of the pathophysiology of diabetes has led to the development of new therapies for diabetes. This article reviews the potential use of these newer pharmacologic agents as adjunctive therapy in T1DM in children and adolescents.

Original languageEnglish (US)
Pages (from-to)370-374
Number of pages5
JournalPediatric Research
Volume65
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Glucagon-Like Peptide 1
Insulin
Islet Amyloid Polypeptide
Gastric Emptying
Glucagon
Therapeutics
Hypoglycemia
Type 2 Diabetes Mellitus
Weight Gain

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

New potential adjuncts to treatment of children with type 1 diabetes mellitus. / Raman, Vandana S.; Heptulla, Rubina A.

In: Pediatric Research, Vol. 65, No. 4, 04.2009, p. 370-374.

Research output: Contribution to journalArticle

Raman, Vandana S. ; Heptulla, Rubina A. / New potential adjuncts to treatment of children with type 1 diabetes mellitus. In: Pediatric Research. 2009 ; Vol. 65, No. 4. pp. 370-374.
@article{3ade3394b5dd4f6ca2ef8efea44bbe26,
title = "New potential adjuncts to treatment of children with type 1 diabetes mellitus",
abstract = "Insulin administration is the primary therapy for type 1 diabetes mellitus (T1DM). Current available insulin therapies do not successfully enable children with T1DM to reach glycemic goals without side effects such as hypoglycemia and weight gain. Pramlintide is a synthetic analog of human amylin that acts in conjunction with insulin to delay gastric emptying and inhibit the release of glucagon and is indicated for use in patients with type 1 and type 2 diabetes. Recent studies in adult patients have examined the role of glucagon-like peptide 1 (GLP-1) and agents that bind to its receptor in type 1 diabetes. It is hypothesized that a major component of the glycemic effect is attributable to the known action of GLP-1 to delay gastric emptying and to inhibit glucagon secretion. Further studies with the use of amylin analogs and long-acting GLP-1 agonists as congeners with insulin in T1DM are indicated in children. In recent years, our better understanding of the pathophysiology of diabetes has led to the development of new therapies for diabetes. This article reviews the potential use of these newer pharmacologic agents as adjunctive therapy in T1DM in children and adolescents.",
author = "Raman, {Vandana S.} and Heptulla, {Rubina A.}",
year = "2009",
month = "4",
doi = "10.1203/PDR.0b013e3181975ee4",
language = "English (US)",
volume = "65",
pages = "370--374",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - New potential adjuncts to treatment of children with type 1 diabetes mellitus

AU - Raman, Vandana S.

AU - Heptulla, Rubina A.

PY - 2009/4

Y1 - 2009/4

N2 - Insulin administration is the primary therapy for type 1 diabetes mellitus (T1DM). Current available insulin therapies do not successfully enable children with T1DM to reach glycemic goals without side effects such as hypoglycemia and weight gain. Pramlintide is a synthetic analog of human amylin that acts in conjunction with insulin to delay gastric emptying and inhibit the release of glucagon and is indicated for use in patients with type 1 and type 2 diabetes. Recent studies in adult patients have examined the role of glucagon-like peptide 1 (GLP-1) and agents that bind to its receptor in type 1 diabetes. It is hypothesized that a major component of the glycemic effect is attributable to the known action of GLP-1 to delay gastric emptying and to inhibit glucagon secretion. Further studies with the use of amylin analogs and long-acting GLP-1 agonists as congeners with insulin in T1DM are indicated in children. In recent years, our better understanding of the pathophysiology of diabetes has led to the development of new therapies for diabetes. This article reviews the potential use of these newer pharmacologic agents as adjunctive therapy in T1DM in children and adolescents.

AB - Insulin administration is the primary therapy for type 1 diabetes mellitus (T1DM). Current available insulin therapies do not successfully enable children with T1DM to reach glycemic goals without side effects such as hypoglycemia and weight gain. Pramlintide is a synthetic analog of human amylin that acts in conjunction with insulin to delay gastric emptying and inhibit the release of glucagon and is indicated for use in patients with type 1 and type 2 diabetes. Recent studies in adult patients have examined the role of glucagon-like peptide 1 (GLP-1) and agents that bind to its receptor in type 1 diabetes. It is hypothesized that a major component of the glycemic effect is attributable to the known action of GLP-1 to delay gastric emptying and to inhibit glucagon secretion. Further studies with the use of amylin analogs and long-acting GLP-1 agonists as congeners with insulin in T1DM are indicated in children. In recent years, our better understanding of the pathophysiology of diabetes has led to the development of new therapies for diabetes. This article reviews the potential use of these newer pharmacologic agents as adjunctive therapy in T1DM in children and adolescents.

UR - http://www.scopus.com/inward/record.url?scp=65349115395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349115395&partnerID=8YFLogxK

U2 - 10.1203/PDR.0b013e3181975ee4

DO - 10.1203/PDR.0b013e3181975ee4

M3 - Article

VL - 65

SP - 370

EP - 374

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 4

ER -